Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Fresenius Kabi Pharmaceutical is a prominent healthcare company in China and a key subsidiary of the global Fresenius Kabi group. The company specializes in providing essential medicines and technologies for infusion, transfusion, and clinical nutrition, serving both critically and chronically ill patients. Its extensive product portfolio includes generic intravenous drugs, infusion therapies, and specialized nutrition products, with a market-leading position in anesthesia and nephrology. Operating significant manufacturing and R&D facilities in Beijing and Wuxi, the company is a vital supplier to the Chinese hospital system. Beijing Fresenius Kabi is also increasingly active in the biosimilars market, expanding its reach into oncology and autoimmune diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Beijing Fresenius Kabi Pharmaceutical.